

Supplementary Appendix

Supplementary Table

Detailed description of the 20 patients which were treated by endovascular embolization and were eligible for the present study.

Patient	Type of vascular malformation	Location	Ruptured	Onyx 18	Cyanoacrylates mixed with iodized oil ¹	¹ ratio
1	dAVF	Transverse Sinus L	No	x		
2	AMV	Occipital lobe L	No	x	x	1:1,5 / 1:2
3	dAVF	Sigmoid sinus R	No	x		
4	dAVF	Sigmoid sinus R	No	x		
5	AVM	Cerebellum	Yes	x		
6	AVM	Occipital lobe L	No	x		
7	dAVF	Transverse sinus L	No	x		
8	dAVF	Transverse sinus L	No	x	x	1:2
9	dAVF	Transverse sinus L	No	x		
10	AVM	Temporal lobe L	No	x		
11	AVM	Occipital lobe L	No	x		
12	AVM	Occipital lobe L	No	x	x	1:2
13	AVM	Occipital lobe L	No	x		
14	AVM	Cerebellum	No	x	x	1:2
15	dAVF	Sigmoid sinus L	No	x		
16	AVM	Occipital lobe L	No	x	x	1:4
17	AVM	Parietal lobe L	No	x	x	1:2 / 1:3 / 1:4
18	AVM	Occipital lobe L	No	x	x	1:2

19	AVM	Frontal lobe L	No	x	x	1:3
20	AVM	Cerebellum	Yes	x		

All 20 patients with AVM or dAVF were treated by endovascular embolization with Onyx 18. While 12 patients of the collective were treated solely with Onyx 18, for 8 of them further embolization with cyanoacrylates mixed with iodized oil of different ratios was performed. The total volume of each agent used for endovascular embolization was not provided in the corresponding reports.

dAVF: dural arteriovenous fistula; AVM: arteriovenous malformation; L: left; R: right.